Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06029036
Other study ID # 22440
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date August 5, 2023
Est. completion date July 31, 2026

Study information

Verified date March 2023
Source Peking University First Hospital
Contact Zhisong He, MD
Phone +8610-83572418
Email wyj7074@sohu.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Scientific Rationale: High risk localized prostate cancer (PCa) is associated with higher rates of biochemical recurrence, clinical recurrence, metastasis and PCa-specific death. Novel hormone therapies(NHT) have shown a significant survival advantage with respect to classical ADT in later stages of PCa and have already been investigated in neoadjuvant setting. PURPOSE: To assess antitumor effect by measuring pathological tumor volume with pathological downstaging following radical prostatectomy + pelvic lymph-node dissection (RP + PLND) for high-risk localized prostate cancer patients.


Recruitment information / eligibility

Status Recruiting
Enrollment 53
Est. completion date July 31, 2026
Est. primary completion date July 31, 2025
Accepts healthy volunteers No
Gender Male
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Male =18 years of age. 2. Able to Sign informed consent form independently. 3. Non-metastatic adenocarcinoma of the prostate. 4. Subjects must have as least one of the following features according to NCCN definition of high-risk: Gleason score =8, or PSA >20ng/ml,or=clinical T3a. 5. Subjects with pelvic lymph node involvement(N1) can be included. 6. Candidate for radical prostatectomy with or without pelvic lymph node dissection as per the investigator. 7. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1. 8. Subjects must have normal organ and marrow function as defined below: Hemoglobin = 9.0 g/dL;Absolute neutrophil count (ANC) = 1,500/mcL; Platelets = 100,000/mcL, independent of transfusions/growth factors within 3 months of treatment start; Serum potassium = 3.5 mmol/L; Serum total bilirubin = 2.0 x upper limit of normal (ULN) (except in subjects with Gilbert's syndrome who have a total bilirubin > 1.5 x ULN, measure direct and indirect bilirubin and if direct bilirubin is = 1.5 x ULN, subject may be eligible);Aspartate aminotransferase (AST), alanine aminotransferase (ALT) = 2.5 x ULN;Serum albumin = 3.0 g/dL;Serum creatinine < 2.0 x ULN. Exclusion Criteria: 1. Prostate cancer with neuroendocrine differentiation or small cell features 2. Distant metastasis based on conventional imaging (clinical stage M1). Nodal disease below the iliac bifurcation (clinical stage N1) is not an exclusion. 3. History of prior systemic or local therapy for prostate cancer, including pelvic radiation for prostate cancer. 4. Subjects who are planning bilateral orchidectomy during the treatment period of the study. 5. Intolerable with darolutamide or ADT treatment. 6. Candidates of other clinical trials. 7. Any prior malignancy within 5 years. 8. Complications include significant cardiovascular disease, active infection, astrointestinal disorders, or any other complications that in the opinion of the investigator. 9. Any condition that in the opinion of the investigator would preclude participation in this study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Darolutamide+ADT
Drug: Darolutamide Darolutamide 600 mg, (two 300 mg tablets) administered orally twice daily. Swallow tablets whole. Take Darolutamide with food. Drug: ADT GnRH agonist per physicians' choice, orchiectomy is excluded

Locations

Country Name City State
China Peking University First Hospital Beijing

Sponsors (3)

Lead Sponsor Collaborator
Peking University First Hospital The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Xijing Hospital of Air Force Military Medical University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of pathological downstaging Percentage of patients with tumor downstaging 6 months
Secondary pCR or MRD Pathologic complete response or Minimal Residual Disease(defined as overall diameter <5 mm) 6 months
Secondary PSM Percentage of patients with positive surgical margins 6 months
Secondary Rate of peri-operative complications including delay in surgery, intra-operative complications, and postoperative complications within 30 days of surgery
Secondary Biochemical complete response PSA <0.1ng/ml prior to RP 6 months
Secondary PSA undetectable rate PSA<0.02 ng/ml 12 months post-RP
Secondary 2-year biochemical progression-free survival, bPFS PSA>0.2 ng/ml 24 months post-RP
Secondary AEs/SAEs The level of AEs defined by NCI-CTCAE v5.0. Safety assessments will be assessed and documented after initiation of study drug, regardless of relationship to study drug. Baseline up to 30 days after the last dose of study drug or before initiation of a new antitumor treatment, whichever occurred first
See also
  Status Clinical Trial Phase
Recruiting NCT05540392 - An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues Phase 1/Phase 2
Recruiting NCT05613023 - A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT Phase 3
Recruiting NCT05156424 - A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer Phase 1/Phase 2
Completed NCT03177759 - Living With Prostate Cancer (LPC)
Completed NCT01331083 - A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer Phase 2
Recruiting NCT05540782 - A Study of Cognitive Health in Survivors of Prostate Cancer
Active, not recruiting NCT04742361 - Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer Phase 3
Completed NCT04400656 - PROState Pathway Embedded Comparative Trial
Completed NCT02282644 - Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry N/A
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06305832 - Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer Phase 2
Recruiting NCT05761093 - Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
Completed NCT04838626 - Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection Phase 2/Phase 3
Recruiting NCT03101176 - Multiparametric Ultrasound Imaging in Prostate Cancer N/A
Completed NCT03290417 - Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer N/A
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Completed NCT01497925 - Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer Phase 1
Recruiting NCT03679819 - Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
Completed NCT03554317 - COMbination of Bipolar Androgen Therapy and Nivolumab Phase 2
Completed NCT03271502 - Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy N/A